Anticoagulation After Intracranial Hemorrhage and Stroke
Learn more about maximizing patients’ benefit from anticoagulation therapy and minimizing risk following intracranial hemorrhage and stroke.
Adult and Pediatric Neurologists, Neurosurgeons, Stroke Neurologists, Neuroradiologists, Diagnostic Radiologists, Critical Care Physicians, Neurointensivists, Emergency Medicine Physicians, Internal Medicine Physicians, Interventional Neuroradiologists, Family Physicians, General Internists, Rehabilitation and Pain Management Specialists, Clinical Pharmacists, as well as other specialists interested in the field of neuroscience.
- Analyze the pros and cons of anticoagulation following ICH or ischemic stroke.
- Select patients who would benefit from early anticoagulation and determine the appropriate anticoagulation strategy with regard to timing of initiation and agents of choice.
Kiwon Lee, M.D., FACP, FAHA, FCCM
Professor of Neurology
Chief of Neurology Service
Chief, Division of Stroke and Critical Care
Director, RWJ Comprehensive Stroke Center
Director, Neuro-Intensive Care Unit
Rutgers, The State University of New Jersey
Robert Wood Johnson Medical School
New Brunswick, N.J.
Kiwon Lee, M.D., indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation or discussion.
Kevin Abrams, M.D., indicated that he is a consultant and shareholder with Keystone Heart.
Guilherme Dabus, M.D., indicated that he is a consultant for Microvention/Terumo, Medtronic, Penumbra and Cerenovus, and on the speakers bureau for Microvention/Terumo, Medtronic and Penumbra. He is a proctor for Medtronic. Dr. Dabus is also a shareholder with Surpass Medical/Stryker, Medina/Medtronic, InNeuro Co and Three Rivers Medical.
Daniel D’Amour, M.D., Felipe De Los Rios, M.D., Karel Fuentes, M.D., Sergio Gonzalez-Arias, M.D., Ph.D., Kunal Patel, M.S., Amy K. Starosciak, Ph.D., and Jayme Strauss, R.N., MSN, indicated that neither they nor their spouse/partner have relevant financial relationships with commercial interest companies, and they will not include off-label or unapproved product usage in their presentations or discussions.
Bruno V. Gallo, M.D., indicated that he is on speakers bureau for Teva Pharmaceuticals and Sunovion Pharmaceuticals. He receives grant support for Medtronic International, Pfizer Pharmaceuticals, Glaxo-SmithKline and St. Jude Medical, Inc. Dr. Gallo serves as a consultant for Cyberonics, Teva Pharmaceuticals, St. Jude Medical, ONS Inc. and Sugimon LLC.
Italo Linfante, M.D., indicated that he is a consultant for Medtronic, Stryker and Penumbra. He is a stockholder with InNeuro Co.
Alberto Pinzon-Ardila, M.D., indicated that he is on the speakers bureau for Sunovion Pharmaceuticals and UCB.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 General certificate of attendance
- 0.50 Florida Board of Pharmacy
This site is supported on the most recent stable releases of the following browsers:
This site is supported on the following mobile devices:
If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.